3-Quinuclidinone hydrochloride is used as an intermediate in the synthesis of the thioetherizing agent cevimeline; it is also employed in the preparation of novel CB1 and CB2 cannabinoid receptor ligands. It serves as an organic and pharmaceutical intermediate in laboratory organic synthesis and pharmaceutical R&D, primarily for the synthesis of azasetron and palonosetron, which are used for the treatment and prevention of nausea and vomiting associated with cancer chemotherapy and radiotherapy, as well as postoperative nausea and vomiting.